The Future of Occupational Therapy Innovation
Key Growth Drivers and Opportunities
Increasing Aging Population: Increasing population is a major driver of business medicine market development, as elderly people often face age -related conditions such as arthritis, strokes, dementia and low mobility that affect their ability to do daily tasks independently. Occupational therapy helps seniors to maintain functional skills, increase their risk of injuries such as increasing their quality of life and fall. As life expectancy increases globally, the demand for tailored rehabilitation, home modifications and support technologies provided through commercial medicine, promotes market expansion in both clinical and home care settings.
Challenges
Occupational therapy faces many challenges in the market that can disrupt its growth. A major issue is a lack of qualified business physicians, especially in rural or undertaking areas, which limits access to care. Additionally, high treatment costs and insufficient insurance coverage in some countries make services ineffective for many patients. The market also struggles with limited awareness about the benefits of commercial medicine, especially between older adults and caregivers. Regulatory variations in regions and slow integration of digital devices in traditional medical settings further complex service distribution and scalability.
Innovation and Expansion
JAIN University Launches Occupational Therapy Bachelor's Program for Up-and-Coming Healthcare Executives
In February 2025, at its School of Allied Healthcare and Sciences, JAIN (Deemed-to-be University), a pioneer in cutting-edge education, has introduced the Bachelor of Occupational Therapy (BOT) degree. In order to fulfill the increasing need for qualified occupational therapists worldwide, this state-of-the-art healthcare program, which is scheduled to start in 2025–2026, will provide students with clinical expertise, rehabilitation procedures, and patient-centric therapy treatments.
The Bachelor of Occupational Therapy program at JAIN (Deemed-to-be University) offers a transformational and skill-focused curriculum that equips students for a fulfilling career in healthcare, especially as the need for rehabilitation and therapy specialists continues to grow.
A New Occupational Therapy Clinic Opened by a University-Council Partnership to Support Cumbrian Health
In November 2024, The University of Cumbria and Cumberland Council announced the opening of a new occupational therapy (OT) assessment facility during Occupational Therapy Week (4–10 Nov). In addition to creating the next generation of qualified occupational therapy practitioners, it will assist the increasing number of people who require assistance from the local authority's Adult Social Care teams.
Working in all health and social care settings, occupational therapists are dual-trained allied health professionals who have received training in both physical and mental health issues. Supporting individuals in their daily activities and enhancing their quality of life and well-being is their special area of attention. This might take place at home, at work, or somewhere else.
Inventive Sparks, Expanding Markets
The key players operating in the occupational therapy market are WebPT, Premise Health., Net Health, CLINICIENT, Optima Health Care, Inc., ClinicSource, Accord Medical Products., Bio-Med Inc., Divine Physiotherapy Equipments, Anyang Xiangyu Medical Equipment Co.,Ltd, Ideal Surgical Company., Alliance Therapy Services, among other domestic and global players.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
NHS trust hands over adult care services to Gloucestershire Council
MAJOR changes to adult social care services in Gloucestershire have been announced. Beginning next year, Gloucestershire County Council will take direct control of several services currently delivered by Gloucestershire Health and Care NHS Foundation Trust. The changes will affect mental health social work, occupational therapy, and housing-related support services. Councillor Dr Kate Usmar, cabinet member for adult services and independence at Gloucestershire County Council, said: "I believe these changes will lead to significant improvements to how we deliver adult social care in Gloucestershire. "There is a clear plan and vision for how we will improve these vital services that truly make a difference to people's lives across the county. "While we will always seek to save public money, this is not a cost-cutting move. "While it is motivated by the need for efficiency, it is with the intention of delivering care to more people and to an even higher standard. "I see this as a significant step on our way to building a model of adult social care that we can be truly proud of." The announcement is part of a wider improvement plan for adult social care and follows recommendations from the Care Quality Commission (CQC) earlier this year. The council will work closely with the NHS trust and other partners to ensure a smooth transition, with a focus on maintaining high-quality care and supporting staff. Sandra Betney, deputy chief executive of Gloucestershire Health and Care NHS Foundation Trust, said: "Our priority will always be ensuring that our communities receive high quality care and support and we will therefore be working alongside Gloucestershire County Council in the coming months to ensure a smooth transition. "We are very proud of our colleagues who work within these services – their skill, dedication and commitment has benefitted many thousands of people across Gloucestershire for many years. "We will do everything we can to now support them as they go through the change process."
Medscape
4 days ago
- Medscape
The QWINT Program: Once-Weekly Insulin Efsitora
This transcript has been edited for clarity. Akshay Jain, MD: Greetings from Chicago. I'm Akshay Jain, endocrinologist from Vancouver, Canada. Joining us at the ADA 85th Scientific Sessions today, we've got a very special guest, Dr Athena Philis-Tsimikas, who is the corporate vice president at Scripps in San Diego. Welcome. Athena Philis-Tsimikas, MD: Thank you so much. Happy to be here. Jain: Dr Philis-Tsimikas is one of the lead investigators of the QWINT trial, looking at new basal insulin efsitora alfa. What do you think is the need to have another new insulin? Philis-Tsimikas: It's a good question, because we have so many amazing new drugs that have come out and that we're seeing here at the ADA this year. Despite that, we know that there are over 800 million people with diabetes across the world, just recently published, and that means that there's still going to be many people that require insulin. We know that about 50%-25% of people will still, at some point, require insulin. I do think that insulin remains relevant, and we need to have new ways to deliver and really make it easier for people to take insulin. Jain: That makes sense. Despite all the new medications, insulin's not going anywhere. It's still going to be the backbone for many people requiring optimal diabetes management. Tell us about the QWINT program. What are the studies talking about, and what are they evaluating? Philis-Tsimikas: The QWINT programs are interesting and exciting. You said it's a basal insulin, but it's actually a once-weekly basal insulin. As opposed to the once daily that we've had for a long time and newer once dailies that were longer, this now takes us even longer. Insulin efsitora was tested in the QWINT trials. It was tested in people naive to insulin, people already on insulin, and in type 1 diabetes— so both type 2 and type 1 diabetes — and looking to see if it was noninferior to daily basal insulin and even if it was superior. Jain: That's great. What did the study show? Philis-Tsimikas: I was the lead author on QWINT-3, which was a basal insulin switch trial. For people already coming in on basal insulin, we switched them to go to either efsitora or degludec. At the end of 26 weeks, we showed that it was noninferior. They had a lowering of their A1c from about 7.8% down to about 7%. It was noninferior. They did not show superiority, but what an amazing finding to know that you could take insulin just once a week and still get your A1c down to just below 7%. Jain: Remarkable ability to drop the injection burden, going from 365 shots a year to just 52 shots a year. That's really uplifting. Where I work in Canada, we've got access to insulin icodec, which is a once-weekly insulin, and that is also helping improve patient outcomes. We are moving forward with our ability to give basal insulin with fewer shots. In your studies, were there any patient reported outcomes that were evaluated? Philis-Tsimikas: There were. We did look at satisfaction questionnaires. Satisfaction questionnaires came out better for those who were on once-weekly insulin efsitora. In addition, we also looked at patient safety, so we wanted to make sure that, while you're getting to those better A1cs, do you really have no difference in hypoglycemia? It did show that — for combined nocturnal, both level 2 and level 3 outcomes — there was no difference in terms of the hypoglycemia rates. Jain: That's a really important thing. One very interesting thing that I saw at the presentation yesterday on the QWINT-1 study is that they looked at level 1 hypoglycemia. Do you want to share some of the results with our audience about that? Philis-Tsimikas: Sure. QWINT-1 was a very interesting study because it gave a fixed dose of this basal once-weekly insulin at intervals of every 4 weeks. If you needed an incremental increase, it increased from 100 to 150, to 250, up to 400. Despite having this fixed-dose adjustment, there was no increase in the level 1 or the level 2/level 3 combined hypoglycemia episodes. It's interesting because in all the other trials of once-weekly insulin, level 1 with icodec and efsitora, both were slightly more elevated in those groups. It's very interesting that in the fixed-dose implementation we did not see that difference. Jain: I think that's remarkable. The safety is very important. It's paramount. Also, it gives more confidence to primary care, especially those who are a little shy of starting insulin. Now, one thing that I'd love to talk to you about is the loading dose concept. This is not something that one is aware of when you are using daily basil insulin. Can you tell us about the need for doing this loading and what exactly the loading entails? Philis-Tsimikas: Right, absolutely. This was found in both the icodec and the efsitora studies that we did. Because this has a very long half-life and it takes a while to get up to a steady state, we do need to give a one-time only starting dose. With efsitora, it was three times what the calculated weekly dose was. You take your daily dose, multiply it by seven to get your weekly dose, and then by three for that one-time starting dose. Icodec was similar in that you had to take it times seven, but then one and a half times, so you gave a 50% extra dose. That starting dose allows you to get up a little bit faster so that you don't run higher blood sugars during that first 2-3-week time period. Jain: That's excellent. The other very interesting thing that I saw about the QWINT-1 study was that 76% of individuals were able to get to a dose with this fixed-dose regimen without requiring more than 400 units a week. It doesn't require too much for that flexible dosing aspect. Do you want to share a little bit more about that? Philis-Tsimikas: I think that was absolutely an interesting part. The fact that you can manage the majority of patients with just this one insulin injection once a week without having to then further titrate in a very detailed way that can be difficult for the patient and the provider, right? So, 76% of the time is remarkable. Jain: I think one thing to also note is that, as clinicians, we are always aware that it's a marathon, not a sprint, right? Sooner or later, as long as you're up-titrating, you'll get to the target range. With the QWINT-1 protocol, for the first month, you're continuing to stay on 100 units. I think it's important to reassure the patients that we will be going up in a gradual manner, so that they're not too worried that the sugar's not coming down that quickly. Philis-Tsimikas: Absolutely. If you think about it, for someone who's insulin naive, that's where they've been running. It might not even make a difference for them. Jain: Exactly. Philis-Tsimikas: For someone who's been on insulin that we're switching over, that might make a little bit of a difference but certainly not for that insulin-naive population. Jain: Any final pearls of wisdom that you want to give to our audience? Philis-Tsimikas: Maybe just that for our patients who were on the study, they were all incredibly happy to be able to convert over to this once-weekly dose. Many did not want to stop, and they're all looking forward to seeing when once-weekly insulin will be available — in the United States, at least. I know you are lucky to have it in Canada and other places in Europe. We're looking forward to it in the United States as well. Jain: Thank you so much for joining us, Dr Philis-Tsimikas. Philis-Tsimikas: Thank you so much.
Time Business News
23-07-2025
- Time Business News
The Future of Occupational Therapy Innovation
Occupational Therapy (OT) is a form of healthcare that helps individuals of all ages develop, heal or maintain the skills required for daily life and work after illness, injury or disability. Professional therapy market is increasing due to several major factors, including older conditions and increasing prevalence of the disabled, increasing aging population, more awareness about rehabilitation services and progress in virtual reality and medical technologies such as robotics. Additionally, early intervention in rising mental health concerns and pediatric care is expanding the scope and demand of professional medical services worldwide. Key Growth Drivers and Opportunities Increasing Aging Population: Increasing population is a major driver of business medicine market development, as elderly people often face age -related conditions such as arthritis, strokes, dementia and low mobility that affect their ability to do daily tasks independently. Occupational therapy helps seniors to maintain functional skills, increase their risk of injuries such as increasing their quality of life and fall. As life expectancy increases globally, the demand for tailored rehabilitation, home modifications and support technologies provided through commercial medicine, promotes market expansion in both clinical and home care settings. Challenges Occupational therapy faces many challenges in the market that can disrupt its growth. A major issue is a lack of qualified business physicians, especially in rural or undertaking areas, which limits access to care. Additionally, high treatment costs and insufficient insurance coverage in some countries make services ineffective for many patients. The market also struggles with limited awareness about the benefits of commercial medicine, especially between older adults and caregivers. Regulatory variations in regions and slow integration of digital devices in traditional medical settings further complex service distribution and scalability. Innovation and Expansion JAIN University Launches Occupational Therapy Bachelor's Program for Up-and-Coming Healthcare Executives In February 2025, at its School of Allied Healthcare and Sciences, JAIN (Deemed-to-be University), a pioneer in cutting-edge education, has introduced the Bachelor of Occupational Therapy (BOT) degree. In order to fulfill the increasing need for qualified occupational therapists worldwide, this state-of-the-art healthcare program, which is scheduled to start in 2025–2026, will provide students with clinical expertise, rehabilitation procedures, and patient-centric therapy treatments. The Bachelor of Occupational Therapy program at JAIN (Deemed-to-be University) offers a transformational and skill-focused curriculum that equips students for a fulfilling career in healthcare, especially as the need for rehabilitation and therapy specialists continues to grow. A New Occupational Therapy Clinic Opened by a University-Council Partnership to Support Cumbrian Health In November 2024, The University of Cumbria and Cumberland Council announced the opening of a new occupational therapy (OT) assessment facility during Occupational Therapy Week (4–10 Nov). In addition to creating the next generation of qualified occupational therapy practitioners, it will assist the increasing number of people who require assistance from the local authority's Adult Social Care teams. Working in all health and social care settings, occupational therapists are dual-trained allied health professionals who have received training in both physical and mental health issues. Supporting individuals in their daily activities and enhancing their quality of life and well-being is their special area of attention. This might take place at home, at work, or somewhere else. Inventive Sparks, Expanding Markets The key players operating in the occupational therapy market are WebPT, Premise Health., Net Health, CLINICIENT, Optima Health Care, Inc., ClinicSource, Accord Medical Products., Bio-Med Inc., Divine Physiotherapy Equipments, Anyang Xiangyu Medical Equipment Co.,Ltd, Ideal Surgical Company., Alliance Therapy Services, among other domestic and global players. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
